Meanwhile, a study shows that Chinese cancer patients, particularly NSCLC patients, with NFE2L2 mutation, can benefit more from ICIs treatment than other treatments including chemo- and radiotherapies [23]. Here, NFE2L2 is linked to non-small cell lung carcinoma.